

## All cause mortality





Table 1: Absolute risk estimates

quantiles	2.5%	25%	50%	75%	97.5%
d.t1.t2	0.0545	0.0606	0.0635	0.0662	0.0715
d.t1.t3	0.0354	0.0456	0.0520	0.0595	0.0754
d.t1.t4	0.0558	0.0689	0.0765	0.0846	0.1033
d.t1.t5	0.0585	0.0636	0.0660	0.0683	0.0735
d.t1.t6	0.0604	0.0677	0.0712	0.0749	0.0838
d.t1.t7	0.0524	0.0592	0.0624	0.0655	0.0727



Absolute log-odds for placebo estimated at -2.5, risk 0.0759.

## Major coronary events





Table 2: Absolute risk estimates

quantiles	2.5%	25%	50%	75%	97.5%
d.t1.t2	0.0385	0.0427	0.0448	0.0470	0.0519
d.t1.t3	0.0258	0.0351	0.0404	0.0464	0.0602
d.t1.t4	0.0416	0.0491	0.0535	0.0584	0.0705
d.t1.t5	0.0452	0.0505	0.0529	0.0550	0.0590
d.t1.t6	0.0458	0.0548	0.0591	0.0632	0.0716
d.t1.t7	0.0453	0.0500	0.0526	0.0561	0.0656



Absolute log-odds for placebo estimated at -2.57, risk 0.0711.

## Major cerebrovascular events





Table 3: Absolute risk estimates

quantiles	2.5%	25%	50%	75%	97.5%
d.t1.t2	0.01839	0.0204	0.0214	0.0225	0.0246
d.t1.t3	0.00795	0.0173	0.0237	0.0325	0.0696
d.t1.t4	0.01148	0.0166	0.0204	0.0248	0.0348
d.t1.t5	0.02171	0.0238	0.0248	0.0258	0.0278
d.t1.t6	0.02094	0.0243	0.0261	0.0280	0.0323
d.t1.t7	0.01791	0.0205	0.0217	0.0228	0.0255



Absolute log-odds for placebo estimated at -3.52, risk 0.0287.

## Discontinuation due to adverse events





Table 4: Absolute risk estimates

quantiles	2.5%	25%	50%	75%	97.5%
d.t1.t2	0.0622	0.0714	0.0767	0.0823	0.0945
d.t1.t3	0.0557	0.0708	0.0798	0.0899	0.1132
d.t1.t4	0.0436	0.0553	0.0624	0.0704	0.0885
d.t1.t5	0.0426	0.0497	0.0538	0.0584	0.0685
d.t1.t6	0.0596	0.0700	0.0760	0.0825	0.0967
d.t1.t7	0.0456	0.0541	0.0591	0.0645	0.0763



Absolute log-odds for placebo estimated at -2.65, risk 0.0661.



## Myalgia





Table 5: Absolute risk estimates

quantiles	2.5%	25%	50%	75%	97.5%
d.t1.t2	0.0196	0.0233	0.0256	0.0284	0.0356
d.t1.t3	0.0135	0.0211	0.0264	0.0327	0.0501
d.t1.t4	0.0176	0.0246	0.0290	0.0344	0.0491
d.t1.t5	0.0177	0.0221	0.0250	0.0284	0.0377
d.t1.t6	0.0217	0.0265	0.0294	0.0331	0.0424
d.t1.t7	0.0135	0.0177	0.0205	0.0238	0.0326



Absolute log-odds for placebo estimated at -3.76, risk 0.0226.

## Transaminase





Table 6: Absolute risk estimates

quantiles	2.5%	25%	50%	75%	97.5%
d.t1.t2	0.02043	0.0273	0.0314	0.0361	0.0478
d.t1.t3	0.02637	0.0529	0.0764	0.1112	0.2261
d.t1.t4	0.01143	0.0190	0.0244	0.0315	0.0527
d.t1.t5	0.00765	0.0105	0.0123	0.0144	0.0196
d.t1.t6	0.01280	0.0178	0.0209	0.0246	0.0343
d.t1.t7	0.00809	0.0117	0.0140	0.0168	0.0243



Absolute log-odds for placebo estimated at -4.39, risk 0.0122.

## CK elevation





Table 7: Absolute risk estimates

quantiles	2.5%	25%	50%	75%	97.5%
d.t1.t2	$4.66e-03$	0.007624	0.00942	0.0115	0.01836
d.t1.t3	$2.07e-05$	0.000249	0.00065	0.0014	0.00472
d.t1.t4	$3.25e-03$	0.005927	0.00775	0.0105	0.02536
d.t1.t5	$4.82e-03$	0.007347	0.00865	0.0103	0.01634
d.t1.t6	$5.30e-03$	0.008373	0.01024	0.0127	0.02072
d.t1.t7	$3.41e-03$	0.006172	0.00797	0.0101	0.01631



Absolute log-odds for placebo estimated at -4.96, risk 0.00693.